Clinical Trials
14 trialsNCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07579234 2026-05-12
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 3 Recruiting
NCT07569757 2026-05-08
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT05611931 2026-04-23
XPORT-EC-042
Karyopharm Therapeutics Inc
Phase 3 Recruiting
NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT04562389 2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT04534725 2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3 Completed